PREVIOUS INTRAVENOUS CHEMOTHERAPY DOES NOT ALTER RESPONSE RATE OR SURVIVAL TIME OF PATIENTS WITH HEPATIC METASTASES FROM COLORECTAL CANCER TREATED BY HEPATIC ARTERY CHEMOTHERAPY

Background : The present paper addressed the issue of whether pretreatment with intravenous (IV) chemotherapy affects response rate or survival in patients receiving hepatic artery chemotherapy (HAC). Methods : Case note reviews of 164 patients treated in a teaching hospital from June 1990 to July 1996 were carried out. Results : The response rate and carcino-embryonic antigen (CEA) fall in the two groups was almost identical. There was a nonsignificant survival advantage in the non-pretreatment group. Conclusions : Previous administration of IV chemotherapy did not affect the CEA response of patients receiving HAC.     

幼儿园824名3－6岁幼儿肝功能、乙肝表面抗原检测结果分析

为了解幼儿的肝功能和ＨＢｓＡｇ携带情况，我们于１９９１年肝炎发病高峰季节对我县四所幼儿园共８２４名幼儿进行了ＡＬＴ、ＴＴＴ、ＺｎＴＴ、ＨＢｓＡｇ检测。结果ＡＬＴ、ＴＴＴ均升高１例，有体征；ＡＬＴ单项升高６例，无症状；ＨＢｓＡｇ阳性５８例，其中９例ＡＬＴ升高，４例ＴＴＴ升高。幼儿园是幼儿集中的地方、同吃、同住、接触密切，对ＨＢｓＡｇ阴性者接种乙肝疫苗，对ＡＬＴ升高者不能忽视以免发生肝炎流行。     

检测各型乙肝患者血小板功能的临床意义

检测198例各型乙肝患者血小板功能的五个项目：血小板总数、粘附试验、聚集试验、血块退缩、血小板第3因子有效性，发现各期乙肝患者血小板功能的异常有显著性差异（P＜0．01）．并提示乙肝患者除有血小板数量的改变外，还有质量的改变，因此，全面的血小板功能检测可作为估计乙肝患者肝损害程度的辅助指标．     

慢性肾脏病患者肾组织蛋白酶B的表达及意义

目的 探讨慢性肾脏病患者肾组织蛋白酶B(cathepsin B，CB)的表达及其与肾组织纤维化的关系。方法 采用免疫组织化学SP法和计算机图像分析系统检测肾组织CB、IV型胶原的表达情况，并以体视学多能目镜测试系统对肾活检组织病理切 片进行形态计量，计算硬化肾小球比率及病变肾小管肾间质比率。结果 CB在近曲小管表达最高，在肾小球和肾小管其他部位表达较少。轻度纤维化组和中度纤维化组CB的表达明显低于无纤维化组。CB表达与Ⅳ型胶原表达、病变肾小管肾间质比率及硬化肾小球比率呈显著负相关。结论 CB主要在肾近曲小管表达，其表达成少是细胞外基质(extracellular matrtx，ECM)降解减少的原因之一，参与肾组织纤维化的发生机制。     

Kynurenine aminotransferase activity in human liver: identity with human hepatic C-S lyase activity and a physiological role for this enzyme

The C-S lyase enzymes are responsible for the generation of mutagenic and cytotoxic metabolites via aberrant drug-metabolising pathways in mammalian tissues. We have examined human hepatic cytosolic, mitochondrial and microsomal fractions for evidence of C-S lyase activity. The cytosolic enzyme was purified using fast protein liquid chromatography over FFQ Sepharose, Mono P and Superose 12. An homogeneous protein (monitored by SDS-PAGE) was obtained following purification, and an 11-fold increase in C-S lyase specific activity was observed. The molecular weight of the enzyme was found to be 37 kDa in denaturing conditions, 82.3 kDa in non-denaturing conditions, and the C-S lyase activity was shown to co-purify with kynurenine aminotransferase activity when the transaminase activity of the enzyme was examined with kynurenine as the substrate.     

MR imaging of the brain in patients with hepatic form of Wilson''s disease

The aim of this study was to detect the sites and frequency of possible lesions by brain magnetic resonance imaging (MRI; 1,5T) in a group of 16 neurologically asymptomatic patients with hepatic form of Wilson's disease (WD; seven untreated and nine under treatment). Abnormal MR findings of the brain were found in 75% of patients. Lesions in brain parenchyma were detected in all untreated, drug-naive patients and in 44% of treated patients. Abnormal signal in globus pallidus, putamen, and caudate nucleus was revealed in 86, 71 and 71% of treated and in 33, 33 and 22% of untreated patients, respectively. In five of eight patients with putaminal pathology (62.5%) and in four of seven patients with caudate nuclei involvement (57%), only proton density 2-weighted sequence (PDW) exhibited sensitivity for lesion detection, with both T1W and long echo T2W sequences being insensitive. This superiority of PDW sequence was even more pronounced in the group of untreated patients in whom 80% of putaminal pathology was visible exclusively on this sequence. The lower frequency of lesions in the group of treated in comparison with untreated patients indicated that they might be reversible in the course of chronic chelating therapy.     

细菌内快速构建两种用于肝纤维化基因治疗的重组复制缺陷型腺病毒

目的 :在大肠杆菌内快速构建两种分别含有人肝细胞生长因子 (hepatic growth factor,HGF)和非分泌型人尿激酶型纤溶酶原激活剂 (urokinase- type plasm inogen activator,u PA) c DNA片段的重组复制缺陷型腺病毒。方法 :分别将人 HGF和 u PA c DNA片段与穿梭载体 p Track- CMV连接 ,线性化后与骨架载体 Ad Easy- 1在大肠杆菌 BJ5 183内同源重组获得腺病毒载体 p Ad HGF和 p Adu PA,经 2 93细胞包装后得到复制缺陷型重组腺病毒 Ad HGF和 Adu PA;将 Ad HGF和 Adu PA分别体外感染肝细胞株 L0 2 ,以 Northern印迹法和 Western印迹法检测两种病毒在肝细胞中的表达。 结果 :连接、重组后通过酶切和测序法筛选出病毒质粒 p Ad HGF和 p Adu PA;经 2 93细胞包装 ,3d后均观察到绿色荧光蛋白明显表达 ,Cs Cl梯度离心纯化最终分别获得 4× 10 1 0 efu/ m l滴度的重组病毒 Ad HGF和 6× 10 1 0 efu/ ml Adu PA;两种病毒体外感染肝细胞 3d后 ,HGF和u PA表达均明显增加。结论 :细菌内同源重组制备复制缺陷型腺病毒 ,纯化过程简单 ,重组腺病毒在肝细胞中均高效表达 ,为肝细胞移植基因治疗肝纤维化提供了新的手段     

提高抗肝癌药物的肝脏浓度并降低心脏,血液浓度的实验研究

实验研究结果表明：阿霉素（ＡＤＭ）在采用推进法注射时，经肝血管或外周静脉途径二者的肝、心与血液浓度均无显著差别．如采用控速缓慢输注法，则经肝血管较经外周静脉在提高肝脏浓度方面具有显著效果，心脏内浓度也有一定程度降低。如在肝血管内输注时与血液净化联合应用，则更能提高上述要求。以上结果将为临床抗癌药介入治疗应用方法的开展提供依据和参考价值。     

门静脉转流对肝硬化大鼠耐受入肝血流阻断时限的影响

目的：探讨门静脉转流对肝硬化大鼠耐受人肝血流阻断时限的影响。方法：观测门静脉转流与非门静脉转流条件下阻断入肝血流不同时程后动物存活率及肝脏能量代谢的变化，包括肝细胞线粒体呼吸控制率（RCR）、肝组织三磷酸腺苷（ATP）含量、动脉血酮体比值（AKBR）。结果：①术后两周存活率：肝硬化大鼠门静脉转流下入肝血流阻断（PBB）-30min组和PBB-45min组为100%，单纯入肝血流阻断（PTC）-30min组、PBB-60min组分别为65%和75％。②肝脏能量代谢：缺血后肝组织ATP、RCR及AKBR均明显下降。再灌注后上述指标逐渐恢复，但随缺血时间延长，升高幅度明显降低，甚至难以恢复。结论：门静脉转流能显著提高肝硬化大鼠常温下耐受入肝血流阻断的时限。